Somewhat Positive Press Coverage Somewhat Unlikely to Impact Compugen (CGEN) Stock Price

News stories about Compugen (NASDAQ:CGEN) have been trending somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compugen earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.6141316027231 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Separately, Zacks Investment Research lowered shares of Compugen from a “hold” rating to a “sell” rating in a research note on Wednesday, November 29th.

Compugen (NASDAQ:CGEN) traded up $0.10 during trading hours on Tuesday, reaching $2.45. 163,542 shares of the company were exchanged, compared to its average volume of 125,406. Compugen has a 1-year low of $2.25 and a 1-year high of $6.30.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Compugen (CGEN) Stock Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/compugen-cgen-getting-somewhat-favorable-news-coverage-study-finds.html.

About Compugen

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Insider Buying and Selling by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply